PRTK Paratek Pharmaceuticals, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

PRTK [NASD]

Paratek Pharmaceuticals, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-3.50	Insider Own	4.30%	Shs Outstand	41.64M	Perf Week	4.81%
Market Cap	201.66M	Forward P/E	-	EPS next Y	-0.59	Insider Trans	-1.94%	Shs Float	39.06M	Perf Month	-14.71%
Income	-120.80M	PEG	-	EPS next Q	-0.06	Inst Own	47.30%	Short Float	9.43%	Perf Quarter	-1.51%
Sales	22.90M	P/S	8.81	EPS this Y	-10.20%	Inst Trans	0.06%	Short Ratio	6.33	Perf Half Y	24.80%
Book/sh	-1.33	P/B	-	EPS next Y	68.10%	ROA	-47.60%	Target Price	-	Perf Year	7.51%
Cash/sh	4.42	P/C	1.04	EPS next 5Y	-	ROE	323.90%	52W Range	2.50 - 6.41	Perf YTD	13.65%
Dividend	-	P/FCF	-	EPS past 5Y	12.90%	ROI	-52.40%	52W High	-28.55%	Beta	1.45
Dividend %	-	Quick Ratio	5.00	Sales past 5Y	30.70%	Gross Margin	79.20%	52W Low	83.20%	ATR	0.35
Employees	102	Current Ratio	5.30	Sales Q/Q	393.80%	Oper. Margin	-	RSI (14)	47.21	Volatility	4.01% 8.18%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	39.80%	Profit Margin	-	Rel Volume	0.64	Prev Close	4.48
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 10 BMO	Payout	-	Avg Volume	582.14K	Price	4.58
Recom	1.70	SMA20	-1.61%	SMA50	-3.80%	SMA200	14.32%	Volume	374,118	Change	2.23%

Jan-08-20

Initiated

WBB Securities

Speculative Buy

Jan-02-19

Initiated

Canaccord Genuity

Buy

$14

Nov-23-18

Reiterated

H.C. Wainwright

Buy

$55 → $22

Aug-27-18

Initiated

BofA/Merrill

Neutral

$13

Mar-02-18

Downgrade

Raymond James

Strong Buy → Outperform

Oct-24-17

Initiated

Guggenheim

Buy

$44

Jul-18-17

Reiterated

H.C. Wainwright

Buy

$36 → $43

May-19-17

Initiated

Raymond James

Strong Buy

Apr-11-17

Reiterated

H.C. Wainwright

Buy

$33 → $36

Apr-04-17

Reiterated

Wedbush

Outperform

$30 → $34

Apr-04-17

Initiated

Wedbush

Outperform

$30

Oct-27-16

Resumed

Leerink Partners

Outperform

$23

Jun-17-16

Reiterated

H.C. Wainwright

Buy

$31 → $34

May-13-16

Initiated

Robert W. Baird

Outperform

$30

Mar-30-16

Resumed

Cantor Fitzgerald

Buy

$27

Feb-29-16

Initiated

H.C. Wainwright

Buy

$32

Jul-22-15

Initiated

Gabelli & Co

Buy

$34

May-15-15

Initiated

Leerink Partners

Outperform

May-12-15

Initiated

Cantor Fitzgerald

Buy

$35

May-11-15

Initiated

Guggenheim

Buy

$38

Aug-05-20 04:01PM	Paratek Pharmaceuticals to Present at Two August 2020 Healthcare Conferences GlobeNewswire
Aug-03-20 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
12:31PM	Paratek Pharmaceuticals (PRTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-28-20 04:01PM	Paratek Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10, 2020 GlobeNewswire
12:33PM	Will Paratek Pharmaceuticals (PRTK) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-05-20 03:05PM	Should You Avoid Paratek Pharmaceuticals Inc (PRTK)? Insider Monkey
Jun-12-20 04:46PM	Edited Transcript of PRTK earnings conference call or presentation 11-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-29-20 08:30AM	Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of Stockholders GlobeNewswire
May-28-20 08:00AM	Paratek Pharmaceuticals to Present at Jefferies 2020 Virtual Healthcare Conference GlobeNewswire
May-11-20 04:05PM	Paratek Pharmaceuticals to Present at Bank of America Securities 2020 Health Care Conference GlobeNewswire
07:55AM	Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:14AM	Paratek Pharmaceuticals: Q1 Earnings Insights Benzinga
06:30AM	Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million GlobeNewswire
Apr-30-20 08:00AM	Paratek Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11, 2020 GlobeNewswire -7.47%
Apr-28-20 12:14PM	Will Paratek Pharmaceuticals Continue to Surge Higher? Zacks
Apr-14-20 12:26PM	Seth Klarman Dials Down Akebia Therapeutics Stake GuruFocus.com
Apr-02-20 08:00AM	Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for All FDA Required Post-marketing Studies for NUZYRA (omadacycline) GlobeNewswire
Apr-01-20 08:00AM	Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for Security Requirements and U.S. Onshoring of the Manufacturing Supply Chain for NUZYRA (omadacycline) GlobeNewswire -5.71%
Mar-14-20 10:55AM	Paratek Pharmaceuticals, Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock? Simply Wall St.
Mar-10-20 05:12PM	Edited Transcript of PRTK earnings conference call or presentation 25-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
04:01PM	Paratek Pharmaceuticals Announces the Submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA (omadacycline) GlobeNewswire
Mar-02-20 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-27-20 11:50AM	Paratek Pharmaceuticals, Inc. Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates Simply Wall St.
Feb-26-20 08:00AM	Paratek Pharmaceuticals to Present at the SVB Leerink 9th Annual Global Healthcare Conference GlobeNewswire +20.00%
Feb-25-20 05:35PM	Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:01PM	Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA® (omadacycline) Net Sales of $11.5 Million GlobeNewswire
Feb-24-20 07:00AM	Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China Region GlobeNewswire
Feb-17-20 01:36PM	Is Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) A Volatile Stock? Simply Wall St.
Feb-13-20 04:01PM	Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020 GlobeNewswire
Jan-14-20 03:12PM	Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020 Zacks -5.33%
Dec-20-19 08:38AM	Are Options Traders Betting on a Big Move in Paratek Pharmaceuticals (PRTK) Stock? Zacks
Dec-19-19 09:33PM	Why this King of Prussia biopharma's stock rose 32% Thursday American City Business Journals +32.20%
08:53AM	Paratek's stock rockets on government contract MarketWatch
07:52AM	The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga
Dec-18-19 05:12PM	Paratek Awarded BARDA Project BioShield Contract for NUZYRA® GlobeNewswire
Dec-13-19 03:06PM	Is Paratek Pharmaceuticals Inc (PRTK) Going to Burn These Hedge Funds? Insider Monkey +5.48%
Dec-10-19 12:22PM	Seth Klarman Pares Paratek Pharmaceuticals Stake GuruFocus.com
Dec-06-19 08:00AM	12 Biotech Stocks Primed For A Short Squeeze Benzinga
Dec-02-19 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-30-19 11:02AM	Penny Stocks to Buy Using Technical Analysis for December 2019 Investopedia
Nov-28-19 06:59PM	Edited Transcript of PRTK earnings conference call or presentation 12-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-13-19 12:14PM	Did Changing Sentiment Drive Paratek Pharmaceuticals's (NASDAQ:PRTK) Share Price Down A Painful 79%? Simply Wall St. -8.19%
Nov-12-19 05:15PM	Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019 GlobeNewswire
Nov-05-19 10:31AM	Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out for Zacks +24.53%
Nov-04-19 04:05PM	Paratek Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019 GlobeNewswire
Nov-01-19 04:05PM	Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
07:38AM	The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance Benzinga
Oct-31-19 04:05PM	Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections GlobeNewswire
Oct-29-19 10:32AM	Earnings Preview: Paratek Pharmaceuticals (PRTK) Q3 Earnings Expected to Decline Zacks
Oct-18-19 07:07AM	The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe Benzinga -6.36%
Oct-17-19 04:05PM	Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia GlobeNewswire
Oct-01-19 04:30PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
10:07AM	Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 PR Newswire
Sep-25-19 08:00AM	Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) Development Program at IDWeek 2019 GlobeNewswire
Sep-24-19 08:50AM	Paratek Pharmaceuticals (PRTK) Catches Eye: Stock Jumps 10.2% Zacks
Sep-23-19 01:16PM	Seth Klarman Further Increases Translate Bio Stake GuruFocus.com +10.22%
Sep-10-19 01:58PM	Baupost's Seth Klarman Dives Further Into Translate Bio GuruFocus.com +9.57%
12:33PM	Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Sep-09-19 08:00AM	Paratek Mourns Passing of Co-founder Dr. Stuart Levy GlobeNewswire +18.25%
Sep-04-19 08:00AM	Paratek Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference GlobeNewswire
Sep-03-19 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-30-19 01:31PM	Seth Klarman's Small Biotech Holdings GuruFocus.com +10.32%
08:00AM	The Lancet Infectious Diseases Publishes Results from Parateks Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections GlobeNewswire
Aug-26-19 04:05PM	Paratek Pharmaceuticals to Present at Robert W. Bairds 2019 Global Healthcare Conference GlobeNewswire
Aug-13-19 02:07AM	Edited Transcript of PRTK earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-06-19 05:45PM	Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019 GlobeNewswire
Aug-01-19 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jul-29-19 04:05PM	Paratek Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 6, 2019 GlobeNewswire
Jul-25-19 10:33AM	Earnings Preview: Paratek Pharmaceuticals (PRTK) Q2 Earnings Expected to Decline Zacks
Jul-17-19 04:02PM	Melinta (MLNT) Announces Preliminary Product Sales for Q2 Zacks -6.93%
Jul-10-19 07:00AM	What Type Of Shareholder Owns Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK)? Simply Wall St.
Jul-05-19 03:59PM	Heres What Hedge Funds Think About Paratek Pharmaceuticals Inc (PRTK) Insider Monkey
Jul-01-19 09:13AM	X-Biotix Therapeutics Joins Antimicrobials Working Group PR Newswire
Jun-25-19 04:01PM	Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman GlobeNewswire
Jun-20-19 11:48AM	Biotech companies dominate fastest-growing public companies list again American City Business Journals
11:13AM	Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019 PR Newswire
Jun-07-19 09:27AM	Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections PR Newswire
May-20-19 07:15AM	Edited Transcript of PRTK earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents -6.81%
May-08-19 05:25PM	Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:25PM	Paratek: 1Q Earnings Snapshot Associated Press
04:05PM	Parateks NUZYRA (omadacycline) Generates Net Sales of $1.3 Million in the First Eight Weeks on the U.S. Market GlobeNewswire
May-01-19 10:32AM	Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-30-19 04:05PM	Paratek Pharmaceuticals to Report First Quarter 2019 Financial Results on May 8, 2019 GlobeNewswire
Apr-20-19 09:27AM	Should You Be Pleased About The CEO Pay At Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) Simply Wall St.
Apr-15-19 04:30PM	Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA (Omadacycline) with New ECCMID 2019 Data Presentations GlobeNewswire -6.33%
Apr-12-19 10:08AM	Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-04-19 08:30AM	Paratek Pharmaceuticals Presenting New Data from NUZYRA (Omadacycline) Development Program at ECCMID 2019 GlobeNewswire
Apr-01-19 09:05AM	Paratek Pharmaceuticals Receives American Chemical Society 2019 Heroes of Chemistry Award GlobeNewswire +5.41%
08:10AM	Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Mar-28-19 08:00AM	Paratek Pharmaceuticals to Present at the 2019 H.C Wainwright Global Life Sciences Conference GlobeNewswire
Mar-20-19 01:35PM	Seth Klarman's Small Caps: Worth a Look? GuruFocus.com
Mar-18-19 08:00AM	Paratek Pharmaceuticals Announces Management Change GlobeNewswire
Mar-07-19 12:47PM	What Should Investors Know About Paratek Pharmaceuticals, Inc.s (NASDAQ:PRTK) Future? Simply Wall St.
Mar-05-19 07:49PM	Edited Transcript of PRTK earnings conference call or presentation 27-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-01-19 04:30PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:00AM	Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-27-19 09:08PM	Paratek Pharmaceuticals Inc (PRTK) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM	Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Haskel William M.	Sr. VP, Sec. & General Counsel	May 12	Sale	4.75	4,666	22,164	198,690	May 14 06:42 PM
Brenner Randall B.	Chief Development & Regulatory	May 12	Sale	4.75	6,198	29,441	130,813	May 14 06:38 PM
Woodrow Adam	President & Chief Commercial	May 12	Sale	4.75	4,798	22,791	270,673	May 14 06:30 PM
Loh Evan	CEO	May 12	Sale	4.75	9,595	45,576	552,008	May 14 06:27 PM
BIGHAM MICHAEL	Exec. Chairman of the Board	May 12	Sale	4.68	12,250	57,330	542,167	May 14 06:23 PM
Haskel William M.	Sr. VP, Sec. & General Counsel	Dec 12	Sale	3.10	2,864	8,878	158,356	Dec 16 06:11 PM
Brenner Randall B.	Chief Development & Regulatory	Dec 12	Sale	3.10	6,278	19,462	92,011	Dec 16 06:08 PM
Loh Evan	CEO	Dec 12	Sale	3.10	14,514	44,993	417,603	Dec 16 06:06 PM
Woodrow Adam	President & Chief Commercial	Dec 12	Sale	3.10	4,401	13,643	207,971	Dec 16 06:03 PM
Woodrow Adam	President & Chief Commercial	Oct 08	Sale	3.82	5,322	20,330	212,372	Oct 08 08:58 PM
Loh Evan	CEO	Oct 08	Sale	3.82	7,818	29,865	432,117	Oct 08 08:55 PM
Brenner Randall B.	Chief Development & Regulatory	Oct 08	Sale	3.82	5,049	19,287	98,289	Oct 08 08:45 PM
Loh Evan	CEO	Oct 03	Sale	3.98	16,265	64,735	413,935	Oct 07 05:13 PM
Brenner Randall B.	Chief Development & Regulatory	Oct 03	Sale	3.98	7,674	30,543	91,338	Oct 07 05:10 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience